Stocks Health care BFRI
NASDAQ · Health careBiofrontera Inc. (BFRI)
Biofrontera Inc. brought in $46.2M of revenue over the twelve months to June 30, 2026, up 17.8% from a year earlier. It posted a net loss of $6.4M. In fiscal 2025 capital spending exceeded operating cash flow by $13.4M. At June 30, 2026 it held $4.7M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
Watch BFRI in 60 secondsWhat Biofrontera Inc. does
Biofrontera Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker BFRI.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $41.7M | -$10.5M | -$1.04 | -$13.4M |
| 2024 | $37.3M | -$17.8M | -$3.22 | -$10.3M |
| 2023 | $34.1M | -$20.1M | -$13.02 | -$24.9M |
| 2022 | $28.7M | -$640K | -$0.61 | -$16.2M |
| 2021 | $24.1M | -$37.7M | -$4.28 | n/a |
| 2021 | $18.8M | -$11M | -$479.48 | n/a |
Full financial statements: income, balance sheet and cash flow
Where BFRI ranks in Health care
Latest SEC filings
What Biofrontera Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 14, 2026Other event 8-K
- August 13, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 33% to $12M versus the same quarter last year; diluted EPS -$0.05 versus -$0.57.
- August 13, 2026
- August 12, 2026Passive stake changed SCHEDULE 13G/A
- July 22, 2026
- July 22, 2026Annual report (amended) 10-K/A · period to December 31, 2025Revenue rose 12% to $41.7M versus the prior year; diluted EPS -$1.04 versus -$3.22.
- June 17, 2026
- May 14, 2026Quarterly report 10-Q · period to March 31, 2026Revenue rose 17% to $10.1M versus the same quarter last year; diluted EPS -$0.41 versus -$0.47.
- May 14, 2026
- April 30, 2026Proxy statement DEF 14A
Insider trades
What the people running Biofrontera Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 2 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| July 28, 2026 | Leffler Eugene FrederickChief Financial Officer | Exercised options | 31,250 | - |
| July 28, 2026 | Luebbert HermannCEO & Chairman, Director | Exercised options | 62,500 | - |
Who owns BFRI
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Deutsche Balaton Aktiengesellschaft13D, may seek influence with 7 related filers | 19.99% | September 19, 2025 |
| Laurence W. Lytton13G, passive | 9.99% | November 14, 2024 |
| Rosalind Advisors, Inc.13G, passive with 3 related filers | 9.9% | August 12, 2026 |
| Orin Hirschman13G, passive with 1 related filers | 7.9% | January 28, 2026 |
Largest institutional holders
Insiders
2 insiders reported holding 558,961 shares in total, about $659.6K at the last price.
| Holder | Shares |
|---|---|
| Luebbert HermannCEO & Chairman, Director | 352,711 |
| Leffler Eugene FrederickChief Financial Officer | 206,250 |
Questions about BFRI
What does Biofrontera Inc. do?
Biofrontera Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker BFRI.
Is Biofrontera Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $6.4M on revenue of $46.2M.
How much revenue does Biofrontera Inc. make?
Over the twelve months to June 30, 2026 Biofrontera Inc. reported revenue of $46.2M. That is 17.8% more than a year earlier.
When did Biofrontera Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the other event from September 14, 2026.
Similar companies
Compare BFRI with
Follow BFRI
Get an email when Biofrontera Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow BFRI: get an email when it filesWhere the numbers come from
Financial figures are the values Biofrontera Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.